about
Statins for children with familial hypercholesterolemiaStatins for children with familial hypercholesterolemiaStatins and its hepatic effects: Newer data, implications, and changing recommendationsEffects of Vaccinium Berries on Serum Lipids: A Meta-Analysis of Randomized Controlled TrialsNon-cardiovascular effects associated with statinsPharmacogenomics of statins: understanding susceptibility to adverse effectsDifferential mitochondrial toxicity screening and multi-parametric data analysisStatin associated hepatic adverse effects: a retrospective review from a regional hospital in sultanate of omanAnticipating the evolution of clinical cholesterol guidelines: implications of recent statin intervention trials.Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease.Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma.Statin therapy and hepatotoxicity: Appraisal of the safety profile of atorvastatin in hyperlipidemic patients.Niacin or ezetimibe for patients with, or at risk of coronary heart diseaseTreating statin-intolerant patientsTherapeutic approach to FSGS in children.Anti-hypercholesterolemic and anti-atherosclerotic effects of polarized-light therapy in rabbits fed a high-cholesterol dietLipid-lowering agents that cause drug-induced hepatotoxicity.How safe is aggressive statin therapy?Drug insight: statins and gastrointestinal cancer.Effectiveness and hepatotoxicity of statins in men seropositive for hepatitis C virus.The safety of rosuvastatin: effects on renal and hepatic function.Safety of statins.Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapySafety of statin therapy in patients with preexisting liver disease.Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network.The myth of statin-induced hepatotoxicity.Mitochondrial and immunoallergic injury increase risk of positive drug rechallenge after drug-induced liver injury: a systematic review.Expert opinion on current therapies for nonalcoholic fatty liver disease.Treatment of nonalcoholic fatty liver disease in adults and children: a closer look at the arsenal.Clinical perspective: statins and the liver--harmful or helpful?Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs.Safety considerations with fenofibrate/simvastatin combination.Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments.Statins for children with familial hypercholesterolemia.The safety of ezetimibe and simvastatin combination for the treatment of hypercholesterolemia.The Different Facets of Dyslipidemia and Hypertension in Atherosclerosis.Statin-induced liver injury in an area endemic for hepatitis B virus infection: risk factors and outcome analysis.Primary Care Physician Perspectives on Barriers to Statin Treatment.ANMCO Position Paper: diagnostic-therapeutic pathway in patients with hypercholesterolaemia and statin intolerance
P2860
Q24194816-94ECC277-5743-479D-9FBE-2B649A1EFF1EQ24234081-D7B63411-7007-41E8-B0E9-7712A558F221Q26767065-E9540729-708A-4636-BA8B-272201458C3AQ26783435-D0185544-1D13-4E92-B6AD-BBBA15E8882BQ27026332-3B08A549-749B-495A-83E0-6C50055449F3Q28079822-AEB9D54B-81B6-4CCE-9E74-22EDC7C1E9C4Q28484406-87CA96C9-4BBB-4BF4-BDF2-E8603F67FA01Q28654581-46C41FE2-A5EC-4256-8E34-19A1BED4D24AQ33508676-0DF330AB-58F7-41B4-BB60-377807879BC8Q33563872-89A78A5A-8485-46F6-B10E-0E7852000412Q33765060-4983AEB4-5B24-4AE5-822A-C5793564FE92Q34169932-63E03777-0850-4B55-ACE8-F465E83012D4Q34300722-D0D62D80-1983-49F0-ABCE-F567CDB82DADQ35110510-36A03A5B-24BA-436D-A631-BC708FC4301EQ35614311-313A5876-69F0-4481-BFCC-EDC3003E1956Q35860330-BD19E817-1B69-4A79-98C6-5EAAD315CD3CQ36103339-48EDC703-34F6-49F4-97D0-6109913869D5Q36587418-3E3132E4-6715-47A9-A8DD-B8ED82DD02C2Q36606882-E72BC556-5B97-4CA2-AA69-8933A4FDB29DQ36837171-A0293BCD-B599-4694-8499-A232B5886ADFQ36945023-3DC24BEB-7750-4A16-AF42-8E72BC12D3F4Q37095088-A29DCDD0-F1CE-4EC2-BDB5-300342640433Q37115301-09614429-56E4-4502-AE1A-BD16F5165D40Q37117878-E6F4F7B9-B72B-40D4-A07D-34FB3F373854Q37473382-FA72E1DD-AED3-4382-850C-9E378476C1A6Q37743155-A8941211-E49E-4096-8E32-375EC106F0E6Q37812059-8988D3E7-0436-4E7F-8AB6-BAA3708CBCCFQ37884620-4B7D6E21-715B-46E6-82BF-F54DC2E21374Q37943719-89608B24-F89E-4747-BE62-23D1E8AE4B6DQ38009719-C4C87BF8-64FD-4C7D-8E32-8CDD99C84FD2Q38020492-B957D83D-E0A1-4E75-97E9-0D06105940E3Q38113494-820A41AF-6799-4914-A1C6-58A1E598358AQ38541832-A9AF96AF-BFED-4712-B934-3C1D4C9BC168Q38644870-FED7C716-DCC4-41B2-9865-329E02C36D1DQ38689931-719A52EC-5020-4850-89BE-BC35AC1E4AF2Q38742876-2337D96A-CF73-4E6F-860B-D3E17B1C915DQ39002325-5A49279C-D4A0-47D4-BED5-B2B20171F3DDQ39752811-8223DCD5-1C91-4730-AAA3-446915BA5907Q40121972-48E18906-F563-4BA7-814A-58E0699E48C3Q41082961-021E2555-2A29-460A-AA78-F3125C4D36F6
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Statins and liver toxicity: a meta-analysis.
@ast
Statins and liver toxicity: a meta-analysis.
@en
type
label
Statins and liver toxicity: a meta-analysis.
@ast
Statins and liver toxicity: a meta-analysis.
@en
prefLabel
Statins and liver toxicity: a meta-analysis.
@ast
Statins and liver toxicity: a meta-analysis.
@en
P2093
P2860
P1433
P1476
Statins and liver toxicity: a meta-analysis.
@en
P2093
Andrew M Peterson
Kristin Miller
Sarah A Spinler
Simon de Denus
P2860
P304
P356
10.1592/PHCO.24.6.584.34738
P407
P577
2004-05-01T00:00:00Z